Loading
Life sciences · Journal article
Journal of Clinical Medicine · September 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background/Objectives: Korean studies reported adverse metabolic changes during the COVID-19 pandemic, but subsequent patterns remain unclear. This study examined metabolic syndrome (MetS) and its components across pre-pandemic, pandemic, and recovery periods among Korean adults. Methods: We analyzed 36,194 adults aged ≥20 years from the 2018–2024 Korea National Health and Nutrition Examination Survey: 11,354 pre-pandemic (2018–2019), 10,200 pandemic (2020–2021), and 14,640 recovery (2022–2024). MetS was defined as ≥3 of five components. Complex-sample analyses and multivariable logistic regression were performed. Sensitivity analysis excluded reduced high-density lipoprotein cholesterol (HDL-C). Results: Weighted MetS prevalence was 29.1%, 30.5%, and 26.4% across the pre-pandemic, pandemic, and recovery periods, respectively. Individual MetS components showed divergent patterns. Abdominal obesity increased during the pandemic and remained elevated during recovery, whereas reduced HDL-C declined markedly during recovery. Compared with the pre-pandemic period, the fully adjusted odds of MetS were not significantly higher during the pandemic (OR, 1.077; 95% CI, 0.999–1.161) but were lower during recovery (OR, 0.845; 95% CI, 0.790–0.903). After excluding reduced HDL-C, the recovery association was attenuated (OR, 0.924; 95% CI, 0.857–0.997). Conclusions: MetS prevalence decreased during recovery, but individual components showed divergent trajectories, with abdominal obesity remaining elevated. Attenuation after excluding reduced HDL-C suggests that lower MetS prevalence should not be interpreted as uniform metabolic recovery.